Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Omalizumab (Xolair): Treatment of Adults and Adolescents (12 Years of Age and above) with Chronic Idiopathic Urticaria [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug.
Omalizumab (Xolair): Treatment of Adults and Adolescents (12 Years of Age and above) with Chronic Idiopathic Urticaria [Internet].
Show details- CDR
CADTH Common Drug Review
- CIU
chronic idiopathic urticaria
- ICUR
incremental cost-utility ratio
- LTRA
leukotriene receptor antagonist
- QALY
quality-adjusted life-year
- SOC
standard of care
- UAS7
Urticaria Activity Score over seven days
- ABBREVIATIONS - Omalizumab (Xolair)ABBREVIATIONS - Omalizumab (Xolair)
- PATIENT INPUT SUMMARY - Omalizumab (Xolair)PATIENT INPUT SUMMARY - Omalizumab (Xolair)
- REVIEW OF OTHER HTA AGENCY REPORTS - Ingenol Mebutate (Picato)REVIEW OF OTHER HTA AGENCY REPORTS - Ingenol Mebutate (Picato)
- DISCUSSION - Edoxaban (Lixiana)DISCUSSION - Edoxaban (Lixiana)
- Ingenol Mebutate (Picato)Ingenol Mebutate (Picato)
Your browsing activity is empty.
Activity recording is turned off.
See more...